JW Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
303
- Stock Symbol
-
02126
- Investments
-
1
- Share Price
-
$0.34
- (As of Thursday Closing)
JW Therapeutics General Information
Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact Information
Website
www.jwtherapeutics.comCorporate Office
- Building B, 5/F, Wison Center
- 666 Haike Road, Pudong New Area
- Shanghai, 200131
- China
Corporate Office
- Building B, 5/F, Wison Center
- 666 Haike Road, Pudong New Area
- Shanghai, 200131
- China
JW Therapeutics Stock Performance
As of 12-Nov-2026, JW Therapeutics’s stock price is $0.34. Its current market cap is $143M with 417M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.34 | $0.33 | $0.18 - $0.48 | $143M | 417M | 1.53M | -$0.12 |
JW Therapeutics Financials Summary
As of 30-Jun-2026, JW Therapeutics has a trailing 12-month revenue of $41.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 50,871 | 96,203 | 829 | (2,989) |
| Revenue | 41,253 | 39,444 | 22,050 | 24,574 |
| EBITDA | (48,441) | (66,729) | (72,075) | (97,496) |
| Net Income | (48,369) | (77,217) | (82,312) | (108,553) |
| Total Assets | 122,629 | 141,051 | 230,184 | 302,753 |
| Total Debt | 37,516 | 37,526 | 57,863 | 44,973 |
JW Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
JW Therapeutics Comparisons
Industry
Financing
Details
JW Therapeutics Competitors (48)
One of JW Therapeutics’s 48 competitors is TME Pharma, a Formerly VC-backed company based in Berlin, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Gamida Cell | Formerly VC-backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
JW Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
JW Therapeutics Patents
JW Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026052052-A1 | Polypeptide for the treatment of diseases associated with gpc3 | Pending | 06-Sep-2024 | ||
| WO-2025237409-A1 | Polypeptide for the treatment of diseases associated with gd2 | Pending | 17-May-2024 | ||
| WO-2025218739-A1 | Polypeptide systems | Pending | 17-Apr-2024 | ||
| WO-2025208784-A1 | Composition for cell culture | Pending | 02-Apr-2024 | ||
| EP-4822021-A1 | Nucleic acid extraction method for engineered cell | Pending | 06-Dec-2023 | C12N15/1003 |
JW Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
JW Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
JW Therapeutics Acquisitions (1)
JW Therapeutics’s most recent deal was a Merger/Acquisition with Syracuse. The deal was made on 20-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Syracuse | 20-Jul-2020 | Merger/Acquisition | Drug Discovery |
JW Therapeutics ESG
Risk Overview
Risk Rating
Updated September, 30, 2022
30.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Biotechnology
Subindustry
of 412
Rank
Percentile
JW Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Syracuse | Hong Kong, Hong Kong | 2018 |
JW Therapeutics FAQs
-
When was JW Therapeutics founded?
JW Therapeutics was founded in 2016.
-
Where is JW Therapeutics headquartered?
JW Therapeutics is headquartered in Shanghai, China.
-
What is the size of JW Therapeutics?
JW Therapeutics has 303 total employees.
-
What industry is JW Therapeutics in?
JW Therapeutics’s primary industry is Biotechnology.
-
Is JW Therapeutics a private or public company?
JW Therapeutics is a Public company.
-
What is JW Therapeutics’s stock symbol?
The ticker symbol for JW Therapeutics is 02126.
-
What is the current stock price of JW Therapeutics?
As of 12-Nov-2026 the stock price of JW Therapeutics is $0.34.
-
What is the current market cap of JW Therapeutics?
The current market capitalization of JW Therapeutics is $143M.
-
What is JW Therapeutics’s current revenue?
The trailing twelve month revenue for JW Therapeutics is $41.3M.
-
Who are JW Therapeutics’s competitors?
TME Pharma, Ayala Pharmaceuticals, Adaptimmune Therapeutics, Gamida Cell, and Kite Pharma are some of the 48 competitors of JW Therapeutics.
-
What is JW Therapeutics’s annual earnings per share (EPS)?
JW Therapeutics’s EPS for 12 months was -$0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
